The Entrepreneurs Fund BV has invested EUR 1.35m in the second closing of a series-A funding round for biotechnology company ProtAffin Biotechnologie AG. Previously, Aescap Venture Management BV and Z-Cube Srl invested EUR 2.65m in the first series-A closing in May 2007. This brings the total funds raised in the series-A financing to EUR 4m. The seed financing of EUR 1.3m was provided by angel investors and Austria Wirtschaftsservice in Vienna. ProtAffin Biotechnology AG is a pre-clinical biotechnology company developing protein-based products targeting inflammation. Its novel class of biologics targets heparin-like glycan structures driving inflammatory processes. ProtAffin was spun-out from the Karl-Franzens University of Graz, Austria in July 2005. It is headquartered in Graz, Austria, and currently has 12 employees.
This is the second deal inked by the GP via Wisequity V, which closed on its €260m hard-cap in July 2019
Pascal Meysson joins from Alcentra and has previous experience at Deutsche Bank and Charterhouse
Mirabaud is reportedly planning to invest via its Living Heritage private equity fund
HIG invested from its Growth Buyout Equity Fund III to acquire Vernacare from Palatine